Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post-transplant cyclophosphamide for treatment of high-risk myeloid neoplasms in children: A retrospective study

A retrospective study analyzed safety and efficacy data of prophylactic donor lymphocyte infusion (pro-DLI) in pediatric patients with high-risk myeloid neoplasms (AML or MDS) who underwent haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis. The cumulative incidences of acute GVHD were 37.0% for grade II-IV and 16.7% for grade III-IV. The 2-year rate of moderate/severe chronic GVHD was 8.1%. At 2 years, the relapse rate was 16.6%, with a GVHD-free relapse-free survival rate of 62.2% and overall survival rate of 87.3%.